PROCEPT BioRobotics investors face September 22 lead-plaintiff deadline in proposed securities class action

A proposed securities class action has been filed on behalf of investors who purchased PROCEPT BioRobotics common stock between February 28, 2024 and February 25, 2026, with any motion to serve as lead plaintiff due by September 22, 2026, according to SueWallSt. A separate July 30 announcement from Grabar Law Office said it is investigating potential fiduciary-duty claims on behalf of current shareholders who bought PRCT shares before February 28, 2024 and still hold them. Both notices center on allegations that Procept failed to disclose an extensive handpiece discount program that encouraged customers to place bulk orders beyond underlying procedure demand, pulling sales forward and inflating reported U.S. handpiece unit sales, recurring revenue metrics and utilization of installed AquaBeam Robotic Systems. The allegations also say the program contributed to excess customer inventory in the field, including claims of more than 10,000 excess units by the end of the class period, and that Procept later disclosed procedure data showing handpiece sales exceeded procedures by 8% to 16% every quarter since the first quarter of 2023. The filings further allege that the inventory buildup led to destocking and optimization efforts and left Procept’s 2025 handpiece sales and revenue guidance without a reasonably achievable factual basis. SueWallSt said PRCT shares fell more than 75%, from about $100 during the class period to less than $25 after the alleged corrective disclosures. No class has been certified.